Patents Issued in April 29, 2008
  • Patent number: 7365026
    Abstract: A semiconductor method of manufacturing involving low-k dielectrics is provided. The method includes depositing a hydrocarbon of the general composition CxHy on the surface of a low-k dielectric. The hydrocarbon layer is deposited by reacting a precursor material, preferably C2H4 or (CH3)2CHC6H6CH3, using a PECVD process. In accordance with embodiments of this invention, carbon diffuses into the low-k dielectric, thereby reducing low-k dielectric damage caused by plasma processing or etching. Other embodiments comprise a semiconductor device having a low-k dielectric, wherein the low-k dielectric has carbon-adjusted dielectric region adjacent a trench sidewall and a bulk dielectric region. In preferred embodiments, the carbon-adjusted dielectric region has a carbon concentration not more than about 5% less than in the bulk dielectric region.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: April 29, 2008
    Assignee: Taiwan Semiconductor Manufacturing Company, Ltd.
    Inventors: Shwang-Ming Jeng, Ming Ling Yeh, Tien-I Bao, Keng-Chu Lin
  • Patent number: 7365027
    Abstract: The use of atomic layer deposition (ALD) to form an amorphous dielectric layer of titanium oxide (TiOx) doped with lanthanide elements, such as samarium, europium, gadolinium, holmium, erbium and thulium, produces a reliable structure for use in a variety of electronic devices. The dielectric structure is formed by depositing titanium oxide by atomic layer deposition onto a substrate surface using precursor chemicals, followed by depositing a layer of a lanthanide dopant, and repeating to form a sequentially deposited interleaved structure. Such a dielectric layer may be used as the gate insulator of a MOSFET, as a capacitor dielectric, or as a tunnel gate insulator in flash memories, because the high dielectric constant (high-k) of the film provides the functionality of a thinner silicon dioxide film, and because the reduced leakage current of the dielectric layer when the percentage of the lanthanide element doping is optimized.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: April 29, 2008
    Assignee: Micron Technology, Inc.
    Inventors: Kie Y. Ahn, Leonard Forbes
  • Patent number: 7365028
    Abstract: The invention includes methods of forming metal oxide and/or semimetal oxide. The invention can include formation of at least one metal-and-halogen-containing material and/or at least one semimetal-and-halogen-containing material over a semiconductor substrate surface. The material can be subjected to aminolysis followed by oxidation to convert the material to metal oxide and/or semimetal oxide. The aminolysis and oxidation can be separate ALD steps relative to one another, or can be conducted in a reaction chamber in a common processing step.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: April 29, 2008
    Assignee: Micron Technology, Inc.
    Inventor: Eugene P. Marsh
  • Patent number: 7365029
    Abstract: Embodiments of the invention generally provide a method for depositing a film containing silicon (Si) and nitrogen (N). In one embodiment, the method includes heating a substrate disposed in a processing chamber to a temperature less than about 650 degrees Celsius, flowing a nitrogen-containing gas into the processing chamber, flowing a silicon-containing gas into the processing chamber, and depositing a SiN-containing layer on a substrate. The silicon-containing gas is at least one of a gas identified as NR2—Si(R?2)—Si(R?2)—NR2 (amino(di)silanes), R3—Si—N?N?N (silyl azides), R?3—Si—NR—NR2 (silyl hydrazines) or 1,3,4,5,7,8-hexamethytetrasiliazane, wherein R and R? comprise at least one functional group selected from the group of a halogen, an organic group having one or more double bonds, an organic group having one or more triple bonds, an aliphatic alkyl group, a cyclical alkyl group, an aromatic group, an organosilicon group, an alkyamino group, or a cyclic group containing N or Si.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: April 29, 2008
    Assignee: Applied Materials, Inc.
    Inventors: R. Suryanarayanan Iyer, Sean M. Seutter, Sanjeev Tandon, Errol Antonio C. Sanchez, Shulin Wang
  • Patent number: 7365030
    Abstract: The present invention provides a process for making a concentrate composition leading to a high internal phase diluted emulsion composition, that can be used for preparation of wet-wipes.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: April 29, 2008
    Assignee: The Procter & Gamble Company
    Inventors: Sylvie Chamba, George Endel Deckner, Mathias Kurt Herrlein, Antonio Martinez-Campoy
  • Patent number: 7365031
    Abstract: A fabric including within its construction a first elongated electrical conductor crossed by a second elongated electrical conductor, the conductors being normally biased apart at a crossover point of said fibres with an air gap between them, whereby application of pressure in a direction substantially normal to a plane of the fabric causes the conductors to make contact. The fabric may be woven, knitted, non-woven or plaited. The fabric can be used as a pressure sensor, switch or other sensor.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: April 29, 2008
    Assignee: Intelligent Textiles Limited
    Inventors: Stanley Shigezo Swallow, Asha Peta-Thomson
  • Patent number: 7365032
    Abstract: A flame retardant union fabric obtained by combining (A) 30 to 70% by weight of a fiber comprising as a main component a flame retardant halogen-containing fiber made of a composition comprising 100 parts by weight of an acrylic copolymer of 30 to 70% by weight of acrylonitrile, 30 to 70% by weight of a halogen-containing vinyl monomer and 0 to 10% by weight of a vinyl monomer copolymerizable with them, 10 to 30 parts by weight of an antimony compound and 8 to 30 parts by weight of a zinc stannate compound, with (B) 70 to 30% by weight of a cellulosic fiber. The flame retardant union fabric shows a high flame resistance which passes the M1 class of NF P 92-503 burning test in France even after the post-treatment.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: April 29, 2008
    Assignee: Kaneka Corporation
    Inventors: Masayuki Adachi, Masaharu Fujii, Toshimitsu Mori, Akio Konishi
  • Patent number: 7365033
    Abstract: Mattress and home furnishing items are made open flame resistant by a fire barrier fabric that includes chlorine-free rayon fiber. The fire barrier fabric at least partially encloses the core of the open flame resistant mattress or home furnishing item. When tested in accordance with the flame resistance test protocols of NFPA 267 or ASTM E 1590, the mattress has a maximum heat release rate of less than 250 kW and a total energy release of less than 40 MJ in the first five minutes of the test. The home furnishing items may be tested under test protocols such as California Technical Bulletin #604 or #117. TEQ of the products of the combustion of chlorine-free fibers, yarns and fabrics is less than or equal to 2 nanograms.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: April 29, 2008
    Assignee: Ventex, Inc.
    Inventors: Harrison Robert Murphy, Juraj Michal Daniel Slavik, II
  • Patent number: 7365034
    Abstract: The present invention is directed to nonwoven materials containing a chemical composition capable of generating carbon dioxide when activated. The present invention provides a latent carbon dioxide gas generating material having a first layer containing fiber and a binder, having a basis weight of from about 25 gsm to about 100 gsm and having inner and outer surfaces, a second layer containing a carbon dioxide gas generating composition, having a basis weight of from about 5 gsm to about 300 gsm and having upper and lower surfaces, and a third layer containing fiber and a binder, having a basis weight of from about 25 gsm to about 100 gsm and having inner and outer surfaces. The inner surface of the first layer is in contact with the upper surface of the second layer, and the inner surface of the third layer is in contact with the lower surface of the second layer.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: April 29, 2008
    Assignee: BKI Holding Corporation
    Inventors: Brian E. Boehmer, Joshua D. Crews, John P. Erspamer
  • Patent number: 7365036
    Abstract: Provided is a crystallized glass spacer for a field emission display resistant to charging with application of an electric field and resistant to chipping or cracking thanks to high fracture toughness. An SiO2—TiO2-based glass is subjected to a reduction and crystallization heat treatment at 600-900° C. in a hydrogen atmosphere or in a mixed atmosphere of hydrogen and nitrogen, to obtain a crystallized glass spacer for FED consisting essentially of, in molar percentage, SiO2: 20-50%, TiO2: 25-45%, MgO+CaO+SrO+BaO+ZnO: 20-50%, B2O3+Al2O3: 0-10% and ZrO2: 0-10%, and containing as a principal crystal at least one crystal selected from BaXTi8O16-based crystals (X=0.8-1.5), Ba2TiSi2O8-based crystals and TiO2-based crystals.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 29, 2008
    Assignee: Asahi Glass Company, Limited
    Inventors: Seiji Miyazaki, Kei Maeda
  • Patent number: 7365037
    Abstract: As a jig material to use under plasma reaction for producing semiconductors the present invention provides a quartz glass having resistance against plasma corrosion, particularly corrosion resistance against fluorine-based plasma gases, and which is usable without causing anomalies to silicon wafers; the present invention furthermore provides a quartz glass jig, and a method for producing the same. A quartz glass containing 0.1 to 20 wt % in total of two or more types of metallic elements, said metallic elements comprising at least one type of metallic element selected from Group 3B of the periodic table as a first metallic element and at least one type of metallic element selected from the group consisting of Mg, Ca, Sr, Ba, Sc, Y, Ti, Zr, Hf, lanthanoids, and actinoids as a second metallic element, provided that the maximum concentration of each of the second metallic elements is 1.0 wt % or less.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: April 29, 2008
    Assignee: Shin-Etsu Quartz Products Co., Ltd.
    Inventors: Tatsuhiro Sato, Nobumasa Yoshida, Mamoru Endo
  • Patent number: 7365038
    Abstract: Glasses are disclosed which are used to produce substrates in flat panel display devices. The glasses exhibit a density less than about 2.45 gm/cm3 and a liquidus viscosity greater than about 200,000 poises, the glass consisting essentially of the following composition, expressed in terms of mol percent on an oxide basis: 65–75 SiO2, 7–13 Al2O3, 5–15 B2O3, 0–3 MgO, 5–15 CaO, 0–5 SrO, and essentially free of BaO. The glasses also exhibit a strain point exceeding 650° C.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: April 29, 2008
    Assignee: Corning Incorporated
    Inventors: Lisa C. Chacon, Adam J. G. Ellison, George B. Hares, Jeffrey T. Kohli, Josef C. Lapp, Robert Morena
  • Patent number: 7365039
    Abstract: A catalyst composition, method of formation and process of use in the polymerization of olefin monomers, said composition comprising a catalyst compound, an activator capable of converting said catalyst compound into an active catalyst for addition polymerization, optionally a carrier, further optionally a liquid diluent, and a hydroxycarboxylate metal salt additive.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: April 29, 2008
    Assignee: Dow Global Technologies Inc.
    Inventors: Joseph N. Coalter, III, Curt N. Theriault, Jan W. Van Egmond, Roger B. Painter
  • Patent number: 7365040
    Abstract: A process for preparing a cobalt-based Fischer-Tropsch synthesis catalyst includes introducing a soluble modifying component precursor of the formula Mc(OR)x, where Mc is a modifying component selected from the group comprising Si, Ti, Cu, Zn, Zr, Mn, Ba, Ni, Na, K, Ca, Sn, Cr, Fe, Li, Tl, Sr, Ga, Sb, V, Hf, Th, Ce, Ge, U, Nb, Ta, W or La, R is an alkyl or acyl group, and x is an integer having a value of from 1 to 5, onto and/or into a cobalt-based Fischer-Tropsch synthesis catalyst precursor, which comprises a porous pre-shaped catalyst support supporting cobalt in an oxidized form. The resultant modified cobalt-based Fischer-Tropsch synthesis catalyst precursor is reduced to obtain a cobalt-based Fischer-Tropsch synthesis catalyst.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: April 29, 2008
    Assignee: Sasoltechnology (Proprietary) Limited
    Inventors: Peter Jacobus Van Berge, Sean Barradas
  • Patent number: 7365041
    Abstract: An ammoxidation catalyst comprising a molybdenum (component (1)), bismuth (component (2)), at least one element selected from the group consisting of nickel, cobalt, zinc, magnesium, manganese and copper (component (3)) and at least one element selected from the group consisting of lanthanum, cerium, praseodymium and neodymium (component (4)), over which an organic compound is subject to ammoxidation which is a composite oxide fluid bed catalyst, is prepared by i) preparing a first solution that comprises at least a portion of component (1), at least a portion of component (2), and at least a portion of component (3) but none of component (4); ii) preparing a second solution by adding a solution of component (4) to the first solution; and iii) drying the second solution obtained and calcining the solid matter obtained from the drying step.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: April 29, 2008
    Assignee: Dia-Nitrix Co., Ltd.
    Inventors: Kenichi Miyaki, Motoo Yanagita, Kunio Mori
  • Patent number: 7365042
    Abstract: The present invention describes novel pyridine-3-sulfonyl compounds having the formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein. The present invention is also directed lo pesticidal compositions that include a) compounds of formula (II) wherein R1, R2, R3, R4 and R6 are as defined herein and b) a carrier. Moreover, the present invention relates to methods for protecting crops from insect attack by contacting the crop with a pesticidally effective amount of the compound of formula (II). In addition, the present invention includes methods for controlling insects by treating the target species with a pesticidally effective amount of the compound of formula (II).
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: April 29, 2008
    Assignee: BASF Aktiengesellschaft
    Inventors: Gregory J. Haley, Deborah Culbertson, Michael F. Treacy
  • Patent number: 7365043
    Abstract: The present invention relates to a composition and/or system comprising a perfume composition for use in a lipophilic fluid fabric treatment system and methods of making and using same. Such composition provides perfume/fabric substantivity.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 29, 2008
    Assignee: The Procter & Gamble Co.
    Inventors: Keith Homer Baker, Richard Timothy Hartshorn, Robert Richard Dykstra, William Michael Scheper, Mark Robert Sivik, John Christian Haught
  • Patent number: 7365044
    Abstract: A compound and method for rendering a hard disk drive forensically unrecoverable includes a solution comprising cerium ammonium nitrate, hydrochloric acid by mass, and water. When applied to the surface of a platter, the compound sufficiently disrupts or corrupts the platter such that not recovering the information previously stored on the platter is not possible using known data recovery techniques.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 29, 2008
    Assignee: University of New Hampshire
    Inventor: Ihab H. Farag
  • Patent number: 7365045
    Abstract: A cleaning solution is provided for cleaning metal-containing microelectronic substrates, particularly for post etch, via formation and post CMP cleaning. The cleaning solution consists of a quaternary ammonium hydroxide, an organic amine, and water. A preferred cleaning solution consists of tetramethylammonium hydroxide, monoethanolamine, and water. The pH of cleaning solution is greater than 10.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: April 29, 2008
    Assignee: Advanced Tehnology Materials, Inc.
    Inventors: Elizabeth L. Walker, Jeffrey A. Barnes, Shahriar Naghshineh, Kevin P. Yanders
  • Patent number: 7365046
    Abstract: A method for stripping a floor using a concentrate prepared by mixing a substantially nonchlorinated concentrate containing a floor finish solvent and an at least partially unactivated water thickener. The concentrate is diluted merely with water at an intended use location to activate the water thickener and noticeably increase within ten minutes or less the viscosity of the resulting mixture, then applied to a hardened floor finish atop a floor and allowed to soften or dissolve the floor finish so that the finish may be removed from the floor.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: April 29, 2008
    Assignee: Ecolab Inc.
    Inventors: Gregory G. Griese, Mark D. Levitt, Brian R. Leafblad, Minyu Li, Robert D. P. Hei
  • Patent number: 7365047
    Abstract: This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: April 29, 2008
    Assignee: The Regents of the University of California
    Inventor: Joseph R. Pisegna
  • Patent number: 7365049
    Abstract: The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: April 29, 2008
    Assignee: Vitateg Biotechnology GmbH
    Inventors: Michael Becker-Andre, Hans Dieplinger, Charlotte Teunissen, Lidija Jerkovic
  • Patent number: 7365050
    Abstract: The present invention provides a method of reducing or preventing a drug-related effect or behavior in a subject by inhibiting N-type calcium channels. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a drug-related effect or behavior. These methods involve assaying test agent binding to N-type calcium channels or channel subunits. Alternatively, test agents can be screened for their ability to alter the level of N-type calcium channels, channel subunit polypeptide or RNA, or the depolarization-induced inward calcium current mediated by these channels. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for a drug-related effect or behavior based on comparison to the corresponding level for a control population.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: April 29, 2008
    Assignee: The Regents of the University of California
    Inventors: Robert O. Messing, Philip M. Newton
  • Patent number: 7365051
    Abstract: The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or cartilage-inducing protein or protein mixture and preferably one or several proteins from the TGF-? superfamily, preferably MP52 or a DNA sequence coding therefor and B is a carrier matrix composed of calcium phosphate ceramics with an interconnecting microporosity which already alone has bone-inducing properties. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones as well as to treat damage to cartilage and/or bone tissue.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: April 29, 2008
    Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
    Inventors: Michael Paulista, Jens Pohl, Joachim Pabst, Helmut Heide
  • Patent number: 7365052
    Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: April 29, 2008
    Assignees: Genetics Institute, LLC., President and Fellows of Harvard College
    Inventors: Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
  • Patent number: 7365053
    Abstract: The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Richard Craig Thompson, Stephen Charles Wilkie, Mark James Zweifel
  • Patent number: 7365054
    Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: April 29, 2008
    Assignees: The Scripps Research Institute, EMD Lexigen Research Center Corp.
    Inventors: Holger N. Lode, Ralph A. Reisfeld, David A. Cheresh, Stephen D. Gillies
  • Patent number: 7365055
    Abstract: The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: April 29, 2008
    Assignee: BTG International Limited
    Inventors: Jamal Temsamani, Roger Lahana, Patrick Mouchet
  • Patent number: 7365056
    Abstract: The invention relates to substituted 9a-N-{N?-[4-(sulfonyl)phenyl]carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-di-hydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series general formula (1), wherein R represents H or cladinosyl moiety and R1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-4-isoxalylamino and 5-methyl-3-isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: April 29, 2008
    Assignee: GlaxoSmithKline istrazivacki centar Zagreb d.o
    Inventors: Nedjeljko Kujundzic, Mirjana Bukvic Krajacic, Karmen Brajsa
  • Patent number: 7365057
    Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: April 29, 2008
    Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, Universita Degli Studi Di Cagliari
    Inventors: Paola LaColla, Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
  • Patent number: 7365058
    Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: April 29, 2008
    Assignee: The Rockefeller University
    Inventors: Markus Stoffel, Mathew N. Poy, Thomas H. Tuschl
  • Patent number: 7365059
    Abstract: A process for producing a photocrosslinked-polysaccharide composition, which comprises: freezing a photoreactive polysaccharide-containing solution comprising a photoreactive polysaccharide in which a photoreactive group is bound to a polysaccharide, an aqueous solvent capable of dissolving the photoreactive polysaccharide, and any one substance selected from the group consisting of alcohol having compatibility with the aqueous solvent, a surfactant and a chelating agent; and irradiating the resulting frozen product with light, and a photocrosslinked-polysaccharide composition obtained by the process.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: April 29, 2008
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 7365060
    Abstract: The present invention is related to a novel method for splitting nucleic acids at specific points on a complementary nucleic acid segment using a dinuclear copper-based compound of Formula I. Additionally, the present invention is related to a novel treatment of cancer, tumors, and cancer cells using a dinuclear copper-based compound of Formula I or a naked ligand of formula II: (Formula I and II).
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: April 29, 2008
    Assignee: University of Maryland
    Inventors: Steven E. Rokita, Kenneth D. Karlin, Kristi J. Humphreys, Lei Li, Narasimha N. Murthy
  • Patent number: 7365061
    Abstract: Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: April 29, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Philip M. Sher, Gang Wu, Wei Meng, Alexandra A. Nirschl, William N. Washburn, Terry Stouch
  • Patent number: 7365062
    Abstract: The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: April 29, 2008
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Robert H. K. Chen, Min A. Xiang
  • Patent number: 7365063
    Abstract: Compounds of the formula I: and pharmaceutically acceptable salts thereof wherein X is N, Y is S, Z is —(CRaRb)r—, A is —NR3, m is 2, n is 1, q is 2, R2 is optioinally substituted aryl or optionally substituted heteroaryl, and p, R1, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I for treatment of central nervous system diseases.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: April 29, 2008
    Assignee: Roche Palo Alto LLC
    Inventors: Nancy Elisabeth Krauss, Meng Sui, Shu-Hai Zhao
  • Patent number: 7365064
    Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: April 29, 2008
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Debnath Bhuniya, Saibal Kumar Das, Gurram Ranga Madhavan, Javed Iqbal, Ranjan Chakrabarti
  • Patent number: 7365065
    Abstract: Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ?CR13— or ?N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6 and the other two must be A5 and when A4 is A5 then all of A1-A3 must be A5; R1 is selected from H, NHY? and COY2, in which case R2 is H, or R1 and R2 may both be methyl or together represent ?O; R3, R4 and R5 are each independently selected from H and lower alkyl groups; R6, R7, R8, R9, R10, R11 and R12 are each independently selected from H, lower alkyl groups, NH2, halogens (F, Cl and Br) O-alkyl, CH2NM2 and CF3; R13 is selected from H, F, Cl Br, NO2, NH2, OH, Me, Et, OMe, NMe2 and CF3; R14 is selected from H, methyl and ethyl; W is selected from ?CH— and ?N—; X is selected from CH2, O, S, SO2, NH and N lower alkyl; Y1 is selected from CO-lower alkyl, CO(CH2)bY3, CO(CH2)bCOY3 and CO(CH)NHCOY3, where b is 1-3; Y2 is selected from OR15, NR16R17 and NH(CH2)CCOY3, wh
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: April 29, 2008
    Assignee: Ferring B.V.
    Inventors: Michael Bryan Roe, Andrzej Roman Batt, David Michael Evans, Gary Robert William Pitt, David Philip Rooker
  • Patent number: 7365066
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Rosanne Bonjouklian, Junkai Liao, William Thomas McMillen, Brandon Lee Parkhurst, Jason Scott Sawyer, Jonathan Michael Yingling, Jeremy Schulenburg York
  • Patent number: 7365067
    Abstract: The present invention provides a compound having the following general formula (I) which is useful as a neurokinin receptor antagonist: (wherein, R1, R2: optionally substituted (hetero)aryl, R3: —CO—R4, —CO—O—R4, etc., R4: alkyl, cycloalkyl, etc., A: CH2, CO, SO2, B: a single bond, etc., D: oxygen, CH2, E: alkylene, alkenylene, n: 1 to 3).
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: April 29, 2008
    Assignee: Sankyo Company, Limited
    Inventors: Takahide Nishi, Toshiyasu Takemoto, Takuya Ikeda, Kiyoshi Morimoto
  • Patent number: 7365068
    Abstract: The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: April 29, 2008
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Dawei Chen, Milind Deshpande, Andrew Thurkauf, Xiangzhu Wang, Yiping Shen, Cuixian Liu, Jesse Quinn, Junko Ohkanda, Shouming Li
  • Patent number: 7365069
    Abstract: The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: April 29, 2008
    Assignee: Bexel Pharmaceuticals Inc.
    Inventors: Shiv Kumar Agarwal, Ravikumar Tadiparthi, Pawan Aggarwal, Savithiri Shivakumar, Debendranath Dey, Biswajit Nag
  • Patent number: 7365070
    Abstract: This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: L1, L2, L3 and Q are linker groups, and Rings A, B and C, and R1-R14 are described in the specification. The compounds are antagonists of melanocortin receptors.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: April 29, 2008
    Assignee: Ore Pharmaceuticals Inc.
    Inventors: Tricia J. Vos, Michael Patane, Michael E. Solomon, Christopher Blackburn, Mihaela D. Danca
  • Patent number: 7365071
    Abstract: The invention relates to novel heterocyclic compounds of general formula (I) and to their salts with a base or an acid: The invention also relates to processes and to intermediates for the preparation of these compounds, and to their use as medicaments, in particular as antibacterials and ?-lactamase inhibitors.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: April 29, 2008
    Inventor: Branislav Musicki
  • Patent number: 7365072
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: April 29, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W Bemis, Francesco G Salituro, John P Duffy, John E Cochran, Edmund M Harrington, Mark A Murcko, Keith P Wilson, Michael Su, Vincent P Galullo
  • Patent number: 7365073
    Abstract: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: April 29, 2008
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Darren B. Dressen, Francine S. Farouz, Christopher Semko, Ying-Zi Xu, Frank Stappenbeck
  • Patent number: 7365074
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 29, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. Cosford, Jeffrey R. Roppe, Lida R. Tehrani, Nicholas D. Smith, Brian Stearns, Dehua Huang, Bowei Wang
  • Patent number: 7365075
    Abstract: The present invention provides Aryl Sulfonamide Compounds having the formula: and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: April 29, 2008
    Assignee: Amgen Inc.
    Inventors: Michael R. DeGraffenreid, Xiao He, Jay P. Powers, Daqing Sun, Xuelei Yan
  • Patent number: 7365076
    Abstract: The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: April 29, 2008
    Assignee: Wyeth
    Inventors: Eugene John Trybulski, Joseph Peter Sabatucci, An Thien Vu, Stephen Todd Cohn, Arthur Attilio Santilli, Lori Krim Gavrin, Fei Ye, Paige Erin Mahaney
  • Patent number: 7365077
    Abstract: Disclosed are piperazine bis-amide derivatives useful as antagonists of the orexin receptor and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: April 29, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Clive Leslie Branch, Christopher Norbert Johnson, David John Nash, Geoffrey Stemp